Xalkori

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
02-12-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
02-12-2022
Public Assessment Report Public Assessment Report (PAR)
02-12-2022

Active ingredient:

crizotinib

Available from:

Pfizer Europe MA EEIG

ATC code:

L01ED01

INN (International Name):

crizotinib

Therapeutic group:

Антинеопластични средства

Therapeutic area:

Карцином, недребноклетъчен белодроб

Therapeutic indications:

XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to.

Product summary:

Revision: 33

Authorization status:

упълномощен

Authorization date:

2012-10-23

Patient Information leaflet

                                60
Б. ЛИСТОВКА
61
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПАЦИЕНТА
XALKORI 200 MG ТВЪРДИ КАПСУЛИ
XALKORI 250 MG ТВЪРДИ КАПСУЛИ
кризотиниб (crizotinib)
ДУМИТЕ „ВИЕ“ И „ВАШИЯ“ СЕ ОТНАСЯТ ЗА
ВЪЗРАСТНИТЕ ПАЦИЕНТИ И ЗА ПОЛАГАЩИТЕ
ГРИЖИ
ЛИЦА ЗА ПЕДИАТРИЧНИ ПАЦИЕНТИ.
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
реакции, уведомете Вашия лекар,
фармацевт или
медицинска сестра. Това включва и
всички възможни нежелани реакции,
неописани в
тази листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява XALKORI и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете XALKORI
3.
Как да приемате XALKORI
4.
Възможни нежелани реакции
5.
Как да съхранявате XALKORI
6.
Съдържание на опаковката и
допълнителна и
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
XALKORI 200 mg твърди капсули
XALKORI 250 mg твърди капсули
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
XALKORI 200 mg твърди капсули
Всяка твърда капсула съдържа 200 mg
кризотиниб (crizotinib).
XALKORI 250 mg твърди капсули
Всяка твърда капсула съдържа 250 mg
кризотиниб (crizotinib).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Твърда капсула
XALKORI 200 mg твърди капсули
Непрозрачна твърда капсула в бяло и
розово, с надпис “Pfizer” на капачето и
“CRZ 200” на
тялото.
XALKORI 250 mg твърди капсули
Розова, непрозрачна твърда капсула с
надпис „Pfizer“ на капачето и „CRZ 250“ на
тялото.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
XALKORI като монотерапия е показан за:

лечение от първа линия на възрастни с
анапластичeн лимфом киназа
(ALK)-положителен авансирал
недребноклетъчен карцином на белия
дроб (NSCLC)

лечение на възрастни с вече лекуван
анапластичeн лимфом киназа
(ALK)-положителен
авансирал недребноклетъчен карцином
на белия дроб (NSCLC)

лечение на възрастни с ROS1-положителен
авансирал недребноклетъчен карцином
на
белия дроб (NSCLC)

лечение на педиатрични пациенти (на
възраст
                                
                                Read the complete document

Similar products

Active ingredient crizotinib

crizotinib

ATC code L01ED01

L01ED01

Marketed by Pfizer Europe MA EEIG

Pfizer Europe MA EEIG

INN (International Name) crizotinib

crizotinib

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 02-12-2022
Summary of Product characteristics Summary of Product characteristics Spanish 02-12-2022
Public Assessment Report Public Assessment Report Spanish 02-12-2022
Patient Information leaflet Patient Information leaflet Czech 02-12-2022
Summary of Product characteristics Summary of Product characteristics Czech 02-12-2022
Public Assessment Report Public Assessment Report Czech 02-12-2022
Patient Information leaflet Patient Information leaflet Danish 02-12-2022
Summary of Product characteristics Summary of Product characteristics Danish 02-12-2022
Public Assessment Report Public Assessment Report Danish 02-12-2022
Patient Information leaflet Patient Information leaflet German 02-12-2022
Summary of Product characteristics Summary of Product characteristics German 02-12-2022
Public Assessment Report Public Assessment Report German 02-12-2022
Patient Information leaflet Patient Information leaflet Estonian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Estonian 02-12-2022
Public Assessment Report Public Assessment Report Estonian 02-12-2022
Patient Information leaflet Patient Information leaflet Greek 02-12-2022
Summary of Product characteristics Summary of Product characteristics Greek 02-12-2022
Public Assessment Report Public Assessment Report Greek 02-12-2022
Patient Information leaflet Patient Information leaflet English 02-12-2022
Summary of Product characteristics Summary of Product characteristics English 02-12-2022
Public Assessment Report Public Assessment Report English 02-12-2022
Patient Information leaflet Patient Information leaflet French 02-12-2022
Summary of Product characteristics Summary of Product characteristics French 02-12-2022
Public Assessment Report Public Assessment Report French 02-12-2022
Patient Information leaflet Patient Information leaflet Italian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Italian 02-12-2022
Public Assessment Report Public Assessment Report Italian 02-12-2022
Patient Information leaflet Patient Information leaflet Latvian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Latvian 02-12-2022
Public Assessment Report Public Assessment Report Latvian 02-12-2022
Patient Information leaflet Patient Information leaflet Lithuanian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 02-12-2022
Public Assessment Report Public Assessment Report Lithuanian 02-12-2022
Patient Information leaflet Patient Information leaflet Hungarian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 02-12-2022
Public Assessment Report Public Assessment Report Hungarian 02-12-2022
Patient Information leaflet Patient Information leaflet Maltese 02-12-2022
Summary of Product characteristics Summary of Product characteristics Maltese 02-12-2022
Public Assessment Report Public Assessment Report Maltese 02-12-2022
Patient Information leaflet Patient Information leaflet Dutch 02-12-2022
Summary of Product characteristics Summary of Product characteristics Dutch 02-12-2022
Public Assessment Report Public Assessment Report Dutch 02-12-2022
Patient Information leaflet Patient Information leaflet Polish 02-12-2022
Summary of Product characteristics Summary of Product characteristics Polish 02-12-2022
Public Assessment Report Public Assessment Report Polish 02-12-2022
Patient Information leaflet Patient Information leaflet Portuguese 02-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 02-12-2022
Public Assessment Report Public Assessment Report Portuguese 02-12-2022
Patient Information leaflet Patient Information leaflet Romanian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Romanian 02-12-2022
Public Assessment Report Public Assessment Report Romanian 02-12-2022
Patient Information leaflet Patient Information leaflet Slovak 02-12-2022
Summary of Product characteristics Summary of Product characteristics Slovak 02-12-2022
Public Assessment Report Public Assessment Report Slovak 02-12-2022
Patient Information leaflet Patient Information leaflet Slovenian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 02-12-2022
Public Assessment Report Public Assessment Report Slovenian 02-12-2022
Patient Information leaflet Patient Information leaflet Finnish 02-12-2022
Summary of Product characteristics Summary of Product characteristics Finnish 02-12-2022
Public Assessment Report Public Assessment Report Finnish 02-12-2022
Patient Information leaflet Patient Information leaflet Swedish 02-12-2022
Summary of Product characteristics Summary of Product characteristics Swedish 02-12-2022
Public Assessment Report Public Assessment Report Swedish 02-12-2022
Patient Information leaflet Patient Information leaflet Norwegian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 02-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 02-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 02-12-2022
Patient Information leaflet Patient Information leaflet Croatian 02-12-2022
Summary of Product characteristics Summary of Product characteristics Croatian 02-12-2022
Public Assessment Report Public Assessment Report Croatian 02-12-2022

Search alerts related to this product

Alerts Xalkori crizotinib

Xalkori crizotinib

View documents history

Documents history Documents history

Xalkori